

Orig: DD/EF w/attachment cc: DCB w/xc attachment cc: DIB ljk 7/28/08

76)(4`


July 25, 2008

Ms. Joanne Givens, District Director Detroit District Office Food and Drug Administration 300 River Place, Suite 5900 Detroit, Michigan 48207

Re: Bi-weekly update following Caraco's response letter dated July 10, 2008.

Dear Ms. Givens,

As indicated in the cover letter to Caraco's FDA Form 483 response, I am providing you this update of the remaining compliance projects associated with the May 2008 FDA inspection.



Caraco remains focused on the completion of this Action Plan as proposed. We have fortified our Quality staff by moving qualified Caraco personnel to the Quality Auditor team. We have also hired a Supervisor of the Quality Assurance Auditors. Additionally, we have received applications and have offers out to potential candidates who will continue to improve compliance, initiate preventative actions and implement corrective actions. As you would expect, we are continually working through our corrective and preventative action plans. As I have conveyed previously we are looking at global improvements and are taking a holistic approach in our improvement plan. We have dedicated Quality Assurance Auditors to specific GMP areas, such as dispensing and the various manufacturing areas. In addition, our manufacturing supervisory staff is being supplemented in all areas as needed.

I appreciate your time to discuss Caraco's commitment to quality and our efforts to improve compliance with me last week. I will continue to provide you with further updates on Caraco's progress in the next $\frac{1}{2}$ $\frac{1}{2}$

Sincerely

Daniel Movens, CEO Caraco Pharmaceutical Laboratories, Ltd.